Exact Mass: 423.2270284
Exact Mass Matches: 423.2270284
Found 407 metabolites which its exact mass value is equals to given mass value 423.2270284,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Idanpramine
C24H29N3O4 (423.21579540000005)
A - Alimentary tract and metabolism > A03 - Drugs for functional gastrointestinal disorders > A03A - Drugs for functional gastrointestinal disorders
Urapidil Hydrochloride
Urapidil hydrochloride is an orally active α1-adrenoceptor antagonist and 5-HT1A receptor agonist with a pIC50 of 6.13 and 4.38 against α1- and α2-adrenoceptor, respectively. Urapidil hydrochloride shows antihypertensive effect[1][2].
Neopetasitenine
Neopetasitenine is found in green vegetables. Neopetasitenine is an alkaloid from Petasites japonicus (sweet coltsfoot
LysoPE(14:1(9Z)/0:0)
C19H38NO7P (423.23857680000003)
LysoPE(14:1(9Z)/0:0) is a lysophosphatidylethanolamine or a lysophospholipid. The term lysophospholipid (LPL) refers to any phospholipid that is missing one of its two O-acyl chains. Thus, LPLs have a free alcohol in either the sn-1 or sn-2 position. The prefix lyso- comes from the fact that lysophospholipids were originally found to be hemolytic however it is now used to refer generally to phospholipids missing an acyl chain. LPLs are usually the result of phospholipase A-type enzymatic activity on regular phospholipids such as phosphatidylcholine or phosphatidic acid, although they can also be generated by the acylation of glycerophospholipids or the phosphorylation of monoacylglycerols. Some LPLs serve important signaling functions such as lysophosphatidic acid. Lysophosphatidylethanolamines (LPEs) can function as plant growth regulators with several diverse uses. (LPEs) are approved for outdoor agricultural use to accelerate ripening and improve the quality of fresh produce. They are also approved for indoor use to preserve stored crops and commercial cut flowers. As a breakdown product of phosphatidylethanolamine (PE), LPE is present in cells of all organisms. [HMDB] LysoPE(14:1(9Z)/0:0) is a lysophosphatidylethanolamine or a lysophospholipid. The term lysophospholipid (LPL) refers to any phospholipid that is missing one of its two O-acyl chains. Thus, LPLs have a free alcohol in either the sn-1 or sn-2 position. The prefix lyso- comes from the fact that lysophospholipids were originally found to be hemolytic however it is now used to refer generally to phospholipids missing an acyl chain. LPLs are usually the result of phospholipase A-type enzymatic activity on regular phospholipids such as phosphatidylcholine or phosphatidic acid, although they can also be generated by the acylation of glycerophospholipids or the phosphorylation of monoacylglycerols. Some LPLs serve important signaling functions such as lysophosphatidic acid. Lysophosphatidylethanolamines (LPEs) can function as plant growth regulators with several diverse uses. (LPEs) are approved for outdoor agricultural use to accelerate ripening and improve the quality of fresh produce. They are also approved for indoor use to preserve stored crops and commercial cut flowers. As a breakdown product of phosphatidylethanolamine (PE), LPE is present in cells of all organisms.
LysoPE(0:0/14:1(9Z))
C19H38NO7P (423.23857680000003)
LysoPE(0:0/14:1(9Z)) is a lysophosphatidylethanolamine or a lysophospholipid. The term lysophospholipid (LPL) refers to any phospholipid that is missing one of its two O-acyl chains. Thus, LPLs have a free alcohol in either the sn-1 or sn-2 position. The prefix lyso- comes from the fact that lysophospholipids were originally found to be hemolytic however it is now used to refer generally to phospholipids missing an acyl chain. LPLs are usually the result of phospholipase A-type enzymatic activity on regular phospholipids such as phosphatidylcholine or phosphatidic acid, although they can also be generated by the acylation of glycerophospholipids or the phosphorylation of monoacylglycerols. Some LPLs serve important signaling functions such as lysophosphatidic acid. Lysophosphatidylethanolamines (LPEs) can function as plant growth regulators with several diverse uses. (LPEs) are approved for outdoor agricultural use to accelerate ripening and improve the quality of fresh produce. They are also approved for indoor use to preserve stored crops and commercial cut flowers. As a breakdown product of phosphatidylethanolamine (PE), LPE is present in cells of all organisms. [HMDB] LysoPE(0:0/14:1(9Z)) is a lysophosphatidylethanolamine or a lysophospholipid. The term lysophospholipid (LPL) refers to any phospholipid that is missing one of its two O-acyl chains. Thus, LPLs have a free alcohol in either the sn-1 or sn-2 position. The prefix lyso- comes from the fact that lysophospholipids were originally found to be hemolytic however it is now used to refer generally to phospholipids missing an acyl chain. LPLs are usually the result of phospholipase A-type enzymatic activity on regular phospholipids such as phosphatidylcholine or phosphatidic acid, although they can also be generated by the acylation of glycerophospholipids or the phosphorylation of monoacylglycerols. Some LPLs serve important signaling functions such as lysophosphatidic acid. Lysophosphatidylethanolamines (LPEs) can function as plant growth regulators with several diverse uses. (LPEs) are approved for outdoor agricultural use to accelerate ripening and improve the quality of fresh produce. They are also approved for indoor use to preserve stored crops and commercial cut flowers. As a breakdown product of phosphatidylethanolamine (PE), LPE is present in cells of all organisms.
(6E,9E,12E)-hexadeca-6,9,12-trienedioylcarnitine
C23H37NO6 (423.26207420000003)
(6E,9E,12E)-Hexadeca-6,9,12-trienedioylcarnitine is an acylcarnitine. More specifically, it is an (6E,9E,12E)-hexadeca-6,9,12-trienedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (6E,9E,12E)-Hexadeca-6,9,12-trienedioylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine (6E,9E,12E)-Hexadeca-6,9,12-trienedioylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
(5E,8E,11E)-Hexadeca-5,8,11-trienedioylcarnitine
C23H37NO6 (423.26207420000003)
(5E,8E,11E)-hexadeca-5,8,11-trienedioylcarnitine is an acylcarnitine. More specifically, it is an (5E,8E,11E)-hexadeca-5,8,11-trienedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (5E,8E,11E)-hexadeca-5,8,11-trienedioylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine (5E,8E,11E)-hexadeca-5,8,11-trienedioylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
(2Z,6Z,10Z)-Hexadeca-2,6,10-trienedioylcarnitine
C23H37NO6 (423.26207420000003)
(2Z,6Z,10Z)-hexadeca-2,6,10-trienedioylcarnitine is an acylcarnitine. More specifically, it is an (2Z,6Z,10Z)-hexadeca-2,6,10-trienedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (2Z,6Z,10Z)-hexadeca-2,6,10-trienedioylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine (2Z,6Z,10Z)-hexadeca-2,6,10-trienedioylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
(2Z,5Z,9Z)-Hexadeca-2,5,9-trienedioylcarnitine
C23H37NO6 (423.26207420000003)
(2Z,5Z,9Z)-hexadeca-2,5,9-trienedioylcarnitine is an acylcarnitine. More specifically, it is an (2Z,5Z,9Z)-hexadeca-2,5,9-trienedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (2Z,5Z,9Z)-hexadeca-2,5,9-trienedioylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine (2Z,5Z,9Z)-hexadeca-2,5,9-trienedioylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
(3E,9E,12E)-Hexadeca-3,9,12-trienedioylcarnitine
C23H37NO6 (423.26207420000003)
(3E,9E,12E)-hexadeca-3,9,12-trienedioylcarnitine is an acylcarnitine. More specifically, it is an (3E,9E,12E)-hexadeca-3,9,12-trienedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (3E,9E,12E)-hexadeca-3,9,12-trienedioylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine (3E,9E,12E)-hexadeca-3,9,12-trienedioylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
2,4-Pyrimidinediamine, 5-(5-(1-piperazinylmethyl)-1,3,4-oxadiazol-2-yl)-N4-propyl-N2-(2-(4-pyridinyl)ethyl)-
Adipamide, 4-amino-2,3-dihydroxy-N-(1-(8-hydroxy-1-oxo-3,4-dihydro-1H-2-benzopyran-3-yl)-3-methylbutyl)-
Aconitane-1,7,8,14-tetrol, 20-ethyl-16-methoxy-4-(methoxymethyl)-, (1alpha,14alpha,16beta)-
C23H37NO6 (423.26207420000003)
senbusine A
C23H37NO6 (423.26207420000003)
A diterpene alkaloid with formula C23H37NO6 that is isolated from several Aconitum species.
([1,2]Sa,32S)-16,26-dihydroxy-25-methoxy-(32rH,34tH,39ac)-3-octahydro-4-oxa-1(1,3),2(1,2)-dibenzena-3(4,2)-quinolizina-cycloheptaphan-5-one|2,6-dihydroxy-5-methoxy-13,14-dihydro-(10alpha)-lythran-12-one|Dihydroverticillatin|Dihydroverticillatine|verticillatine
C25H29NO5 (423.20456240000004)
6beta,14alpha,16beta-trimethoxy-1alpha,4beta,8beta-trihydroxy-N-ethylaconitane|akiramidine
C23H37NO6 (423.26207420000003)
(12S)-46-hydroxy-23-methoxy-(12rH,14tH,19ac)-1-octahydro-3,8-dioxa-2(1,2),4(1,3)-dibenzena-1(4,2)-quinolizina-cyclooctaphan-7-one|Lagerin
C25H29NO5 (423.20456240000004)
L-Valyl-L-amiclenomycyl-L-glutamine|Valylamiclenomycylglutamine
C20H33N5O5 (423.24815680000006)
(3Z,6S)-3-{{2-(1,1-dimethylprop-2-en-1-yl)-7-{[3-(hydroxymethyl)-3-methyloxiran-2-yl]methyl}-1H-indol-3-yl}methylidene}-6-methylpiperazine-2,5-dione|variecolorin N
C24H29N3O4 (423.21579540000005)
Cys Lys Ser Ser
C15H29N5O7S (423.17876040000004)
Cys Ser Lys Ser
C15H29N5O7S (423.17876040000004)
Cys Ser Ser Lys
C15H29N5O7S (423.17876040000004)
Gly Gly Lys Tyr
Gly Gly Tyr Lys
Gly His Asn Pro
Gly His Pro Asn
Gly Lys Gly Tyr
Gly Lys Tyr Gly
Gly Asn His Pro
Gly Asn Pro His
Gly Pro His Asn
Gly Pro Asn His
Gly Tyr Gly Lys
Gly Tyr Lys Gly
His Gly Asn Pro
His Gly Pro Asn
His Asn Gly Pro
His Asn Pro Gly
His Pro Gly Asn
His Pro Asn Gly
Lys Cys Ser Ser
C15H29N5O7S (423.17876040000004)
Lys Gly Gly Tyr
Lys Gly Tyr Gly
Lys Ser Cys Ser
C15H29N5O7S (423.17876040000004)
Lys Ser Ser Cys
C15H29N5O7S (423.17876040000004)
Lys Tyr Gly Gly
Asn Gly His Pro
Asn Gly Pro His
Asn His Gly Pro
Asn His Pro Gly
Asn Pro Gly His
Asn Pro His Gly
Asn Pro Pro Pro
Pro Gly His Asn
Pro Gly Asn His
Pro His Gly Asn
Pro His Asn Gly
Pro Asn Gly His
Pro Asn His Gly
Pro Asn Pro Pro
Pro Pro Asn Pro
Pro Pro Pro Asn
Ser Cys Lys Ser
C15H29N5O7S (423.17876040000004)
Ser Cys Ser Lys
C15H29N5O7S (423.17876040000004)
Ser Lys Cys Ser
C15H29N5O7S (423.17876040000004)
Ser Lys Ser Cys
C15H29N5O7S (423.17876040000004)
Ser Ser Cys Lys
C15H29N5O7S (423.17876040000004)
Ser Ser Lys Cys
C15H29N5O7S (423.17876040000004)
Tyr Gly Gly Lys
Tyr Gly Lys Gly
Tyr Lys Gly Gly
N-Palmitoyl-L-serine phosphoric acid
C19H38NO7P (423.23857680000003)
N,N-BIS(2-HYDROXYETHYL)-N-METHYLHEXADECAN-1-AMINIUM BROMIDE
(3R,4S)-1-benzoyl-4-phenyl-3-tri(propan-2-yl)silyloxyazetidin-2-one
C25H33NO3Si (423.2229588000001)
dansyl-l-serine piperidinium salt
C20H29N3O5S (423.18278240000006)
8H-Indeno[1,2-d]oxazole, 2-[2,2-bis[(4S)-4,5-dihydro-4-(1-methylethyl)-2-oxazolyl]propyl]-3a,8a-dihydro-, (3aS,8aR)
Tocamphyl
C23H37NO6 (423.26207420000003)
p-[(5-cyano-1,6-dihydro-2-hydroxy-1,4-dimethyl-6-oxo-3-pyridyl)azo]-N-(2-ethylhexyl)benzamide
3-INDOXYL PHOSPHATE, BIS(2-AMINO-2-METHYL-1,3-PROPANEDIOL) SALT
n-2-nitrophenylsulfenyl-l-alanine dicyclohexylammonium salt
C21H33N3O4S (423.2191658000001)
(3R,4R)-4-(4-(benzyloxy)phenyl)-1-((R)-1-phenylethyl)piperidin-3-ol hydrochloride
methyl 2-methylprop-2-enoate,2-methylpropyl prop-2-enoate,oxiran-2-ylmethyl 2-methylprop-2-enoate,prop-2-enenitrile
C22H33NO7 (423.22569080000005)
2-[(2S,4R)-1-(9H-fluoren-9-ylmethoxycarbonyl)-4-[(2-methylpropan-2-yl)oxy]pyrrolidin-2-yl]acetic acid
C25H29NO5 (423.20456240000004)
Cyprenorphine
D002492 - Central Nervous System Depressants > D009294 - Narcotics > D053610 - Opiate Alkaloids C78272 - Agent Affecting Nervous System > C67413 - Opioid Receptor Agonist
1-Cyclohexyl-3-(2-morpholinoethyl)carbodiimide metho-p-toluenesulfonate
C21H33N3O4S (423.2191658000001)
3-Methyl(E)-7-[3-(4-fluorophenyl)-1-methylethyl-indol-2-yl]-3-hydroxy-5-oxohept-6-enoate
C25H26FNO4 (423.18457680000006)
N-benzyl-N-[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]-2,4,6-trimethylbenzenesulfonamide
2-(dicyclohexylphosphino)-6-methoxy-N,N-dimethylbiphenyl-2-amine
N-benzyl-N-[(1R,2S)-1-hydroxy-1-phenylpropan-2-yl]-2,4,6-trimethylbenzenesulfonamide
2-O-benzyl 1-O-tert-butyl (2S,4R)-4-[(4-methylphenyl)methyl]-5-oxopyrrolidine-1,2-dicarboxylate
C25H29NO5 (423.20456240000004)
Phosphonic acid 2-dodecanoylamino-hexyl ester propyl ester
C20H42NO6P (423.27496020000007)
1-{[(2S)-3-(diethylamino)-2-hydroxypropyl]amino}-4-({[(2S)-oxiran-2-yl]methyl}amino)anthracene-9,10-dione
C24H29N3O4 (423.21579540000005)
6-{[(3,5-Dioxo-1,2-diphenylpyrazolidin-4-yl)acetyl]amino}hexanoic acid
4-{2-[4-(2-Aminoethyl)piperazin-1-YL]pyridin-4-YL}-N-(3-chloro-4-methylphenyl)pyrimidin-2-amine
C22H26ClN7 (423.19381060000006)
N-butyl-3-{[6-(9H-purin-6-ylamino)hexanoyl]amino}benzamide
4-{[1-Methyl-5-(2-methyl-benzoimidazol-1-ylmethyl)-1H-benzoimidazol-2-ylmethyl]-amino}-benzamidine
5-S-[(1E)-6-amino-1-(2-aminoethylidene)hexyl]-5-thioadenosine
C18H29N7O3S (423.2052484000001)
4-amino-1-(4-{[(3S)-3-ammonio-5-{[ammonio(imino)methyl](methyl)amino}pentanoyl]amino}-2,3,4-trideoxy-beta-D-erythro-hex-2-enopyranosyluronosyl)pyrimidin-2(1H)-one
1-formyl-3-methoxy-10a-methyl-7-(4-methylpent-3-enyl)-9,10-dioxo-4-propan-2-yl-8,8a-dihydro-5H-anthracen-2-olate
(3R,5R)-7-[(1S,2S,6R,8S,8aR)-6-hydroxy-2-methyl-8-[(2S)-2-methylbutanoyl]oxy-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]-3,5-dihydroxyheptanoate
a 1-acyl-sn-glycero-3-phosphoethanolamine (n-C14:1)
C19H38NO7P (423.23857680000003)
a 2-acyl-sn-glycero-3-phosphoethanolamine (n-C14:1)
C19H38NO7P (423.23857680000003)
[(3S)-3-amino-5-[[(2S,3S,6R)-6-(4-amino-2-oxopyrimidin-1-yl)-2-carboxy-3,6-dihydro-2H-pyran-3-yl]amino]-5-oxopentyl]-(diaminomethylidene)-methylazanium
2-[(3S)-3-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]-2-oxo-4,5-dihydro-3H-1-benzazepin-1-yl]acetate
[(2R)-3-[2-aminoethoxy(hydroxy)phosphoryl]oxy-2-hydroxypropyl] tetradec-7-enoate
C19H38NO7P (423.23857680000003)
[(2R)-1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-hydroxypropan-2-yl] (E)-tetradec-7-enoate
C19H38NO7P (423.23857680000003)
(2Z,5Z,9Z)-Hexadeca-2,5,9-trienedioylcarnitine
C23H37NO6 (423.26207420000003)
(6E,9E,12E)-hexadeca-6,9,12-trienedioylcarnitine
C23H37NO6 (423.26207420000003)
(5E,8E,11E)-Hexadeca-5,8,11-trienedioylcarnitine
C23H37NO6 (423.26207420000003)
(2Z,6Z,10Z)-Hexadeca-2,6,10-trienedioylcarnitine
C23H37NO6 (423.26207420000003)
(3E,9E,12E)-Hexadeca-3,9,12-trienedioylcarnitine
C23H37NO6 (423.26207420000003)
Pravachol
D057847 - Lipid Regulating Agents > D000960 - Hypolipidemic Agents > D000924 - Anticholesteremic Agents D004791 - Enzyme Inhibitors > D019161 - Hydroxymethylglutaryl-CoA Reductase Inhibitors D009676 - Noxae > D000963 - Antimetabolites
Carbamic acid, [(1S)-1-[[[4-(dimethylamino)-1-(fluoroacetyl)-4-oxobutyl]amino]carbonyl]-2-methylpropyl]-, phenylmethyl ester
(1R,3S,4S,6R,7R,11Z)-3,6,7,14-tetramethyl-3,8,17-trioxospiro[2,9-dioxa-14-azabicyclo[9.5.1]heptadec-11-ene-4,2-oxiran]-7-yl acetate
3-O-{4,6-dideoxy-4-[(3-hydroxy-3-methylbutanoyl)amino]-2-O-methyl-beta-D-glucopyranosyl}-alpha-L-rhamnopyranose
4-{[3-(4-Chlorobenzyl)-2-methoxyquinolin-6-yl]methyl}piperazine-1-carboximidamide
C23H26ClN5O (423.18257760000006)
4-butoxy-N-[4-[4-(2-methyl-1-oxopropyl)-1-piperazinyl]phenyl]benzamide
1,5-dimethyl-4-oxo-N-[3-(4-propyl-1-piperazinyl)propyl]-2-pyrrolo[3,2-c]quinolinecarboxamide
C24H33N5O2 (423.26341180000003)
[3-(4-Methylphenyl)-1-phenyl-4-pyrazolyl]-[4-(2-pyridinyl)-1-piperazinyl]methanone
3-(3,4-Dimethoxyphenyl)-7-hydroxy-2-methyl-8-[(2-methyl-1-piperidinyl)methyl]-1-benzopyran-4-one
C25H29NO5 (423.20456240000004)
20-Ethyl-16beta-methoxy-4-(methoxymethyl)aconitane-1alpha,6alpha,8,14alpha-tetrol
C23H37NO6 (423.26207420000003)
2-[2,2-dimethyl-6-[4-morpholinyl(oxo)methyl]-3-oxo-1,4-benzoxazin-4-yl]-N-phenylacetamide
4,6-dideoxy-4-(2-methoxypropionamido)-3-C,2-O-dimethyl-L-mannopyranosyl-(1->3)-L-fucopyranose
A disaccharide consisting of N-(2-methoxypropionyl)kansosamine linked via a glycosidic bond (of unspecified configuration) to O-3 of L-fucose.
6-deoxy-3-O-{4,6-dideoxy-4-[(2-methoxypropanoyl)amino]-3-C-methyl-2-O-methyl-L-mannopyranosyl}-L-galactopyranose
N-[(3-fluorophenyl)methyl]-2-[(2S,5R,6R)-6-(hydroxymethyl)-5-[[2-(4-morpholinyl)-1-oxoethyl]amino]-2-oxanyl]acetamide
(1R,9S,10S,11S)-N-(cyclohexylmethyl)-10-(hydroxymethyl)-6-oxo-5-pyrimidin-5-yl-7,12-diazatricyclo[7.2.1.02,7]dodeca-2,4-diene-11-carboxamide
(2S,3R)-5-[(2R)-1-hydroxypropan-2-yl]-8-[2-(3-methoxyphenyl)ethynyl]-3-methyl-2-(methylaminomethyl)-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one
C24H29N3O4 (423.21579540000005)
(2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-8-[2-(3-methoxyphenyl)ethynyl]-3-methyl-2-(methylaminomethyl)-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one
C24H29N3O4 (423.21579540000005)
(2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-8-[2-(3-methoxyphenyl)ethynyl]-3-methyl-2-(methylaminomethyl)-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one
C24H29N3O4 (423.21579540000005)
(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-8-[2-(3-methoxyphenyl)ethynyl]-3-methyl-2-(methylaminomethyl)-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one
C24H29N3O4 (423.21579540000005)
N-[(3-fluorophenyl)methyl]-2-[(2S,5S,6R)-6-(hydroxymethyl)-5-[[2-(4-morpholinyl)-1-oxoethyl]amino]-2-oxanyl]acetamide
(1S,9R,10R,11R)-N-(cyclohexylmethyl)-10-(hydroxymethyl)-6-oxo-5-pyrimidin-5-yl-7,12-diazatricyclo[7.2.1.02,7]dodeca-2,4-diene-11-carboxamide
(1S,9R,10R,11R)-10-(hydroxymethyl)-11-(4-methylpiperazine-1-carbonyl)-12-(pyridin-4-ylmethyl)-7,12-diazatricyclo[7.2.1.02,7]dodeca-2,4-dien-6-one
(2S)-2-[(4S,5S)-5-[(dimethylamino)methyl]-8-[3-(dimethylamino)prop-1-ynyl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-2-yl]-1-propanol
C21H33N3O4S (423.2191658000001)
N-[(3-fluorophenyl)methyl]-2-[(2S,5R,6S)-6-(hydroxymethyl)-5-[[2-(4-morpholinyl)-1-oxoethyl]amino]-2-oxanyl]acetamide
N-[(3-fluorophenyl)methyl]-2-[(2R,5R,6S)-6-(hydroxymethyl)-5-[[2-(4-morpholinyl)-1-oxoethyl]amino]-2-oxanyl]acetamide
N-[(3-fluorophenyl)methyl]-2-[(2R,5R,6R)-6-(hydroxymethyl)-5-[[2-(4-morpholinyl)-1-oxoethyl]amino]-2-oxanyl]acetamide
2-fluoro-N-[(2S,3R,6S)-2-(hydroxymethyl)-6-[2-[[2-(4-morpholinyl)-1-oxoethyl]amino]ethyl]-3-oxanyl]benzamide
2-fluoro-N-[(2R,3R,6R)-2-(hydroxymethyl)-6-[2-[[2-(4-morpholinyl)-1-oxoethyl]amino]ethyl]-3-oxanyl]benzamide
2-fluoro-N-[(2S,3R,6R)-2-(hydroxymethyl)-6-[2-[[2-(4-morpholinyl)-1-oxoethyl]amino]ethyl]-3-oxanyl]benzamide
(1R,9S,10S,11S)-10-(hydroxymethyl)-11-(4-methylpiperazine-1-carbonyl)-12-(pyridin-4-ylmethyl)-7,12-diazatricyclo[7.2.1.02,7]dodeca-2,4-dien-6-one
3-[(3aR,4S,9bR)-4-(hydroxymethyl)-1-(2-methoxy-1-oxoethyl)-2,3,3a,4,5,9b-hexahydropyrrolo[3,2-c]quinolin-8-yl]-N,N-dimethylbenzamide
C24H29N3O4 (423.21579540000005)
3-[(3aR,4R,9bR)-4-(hydroxymethyl)-1-(2-methoxy-1-oxoethyl)-2,3,3a,4,5,9b-hexahydropyrrolo[3,2-c]quinolin-8-yl]-N,N-dimethylbenzamide
C24H29N3O4 (423.21579540000005)
(8R,9S,10S)-N-(4-fluorophenyl)-10-(hydroxymethyl)-9-[4-[(E)-prop-1-enyl]phenyl]-1,6-diazabicyclo[6.2.0]decane-6-carboxamide
(8R,9R,10R)-N-(4-fluorophenyl)-10-(hydroxymethyl)-9-[4-[(E)-prop-1-enyl]phenyl]-1,6-diazabicyclo[6.2.0]decane-6-carboxamide
(8S,9R,10S)-N-(4-fluorophenyl)-10-(hydroxymethyl)-9-[4-[(E)-prop-1-enyl]phenyl]-1,6-diazabicyclo[6.2.0]decane-6-carboxamide
[(1R)-2-[(4-fluorophenyl)methyl]-7-methoxy-1-methyl-1-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,4-piperidine]yl]methanol
(6S,7S,8S)-7-[4-(3-cyclopentylprop-1-ynyl)phenyl]-8-(hydroxymethyl)-2-oxo-N-propyl-1,4-diazabicyclo[4.2.0]octane-4-carboxamide
(6R,7R,8S)-7-[4-(3-cyclopentylprop-1-ynyl)phenyl]-8-(hydroxymethyl)-2-oxo-N-propyl-1,4-diazabicyclo[4.2.0]octane-4-carboxamide
(6S,7S,8R)-7-[4-(3-cyclopentylprop-1-ynyl)phenyl]-8-(hydroxymethyl)-2-oxo-N-propyl-1,4-diazabicyclo[4.2.0]octane-4-carboxamide
2-cyclopropyl-1-[(1R)-2-(cyclopropylmethyl)-1-(hydroxymethyl)-7-methoxy-9-methyl-1-spiro[1,3-dihydropyrido[3,4-b]indole-4,3-azetidine]yl]ethanone
2-(4,4-Diphenyl-1-piperidinobuta-1,3-dienyl)phenyl acetate
N-[(3-fluorophenyl)methyl]-2-[(2R,5S,6R)-6-(hydroxymethyl)-5-[[2-(4-morpholinyl)-1-oxoethyl]amino]-2-oxanyl]acetamide
N-[(3-fluorophenyl)methyl]-2-[(2S,5S,6S)-6-(hydroxymethyl)-5-[[2-(4-morpholinyl)-1-oxoethyl]amino]-2-oxanyl]acetamide
N-[(3-fluorophenyl)methyl]-2-[(2R,5S,6S)-6-(hydroxymethyl)-5-[[2-(4-morpholinyl)-1-oxoethyl]amino]-2-oxanyl]acetamide
2-fluoro-N-[(2R,3S,6R)-2-(hydroxymethyl)-6-[2-[[2-(4-morpholinyl)-1-oxoethyl]amino]ethyl]-3-oxanyl]benzamide
2-fluoro-N-[(2S,3S,6S)-2-(hydroxymethyl)-6-[2-[[2-(4-morpholinyl)-1-oxoethyl]amino]ethyl]-3-oxanyl]benzamide
2-fluoro-N-[(2S,3S,6R)-2-(hydroxymethyl)-6-[2-[[2-(4-morpholinyl)-1-oxoethyl]amino]ethyl]-3-oxanyl]benzamide
2-fluoro-N-[(2R,3S,6S)-2-(hydroxymethyl)-6-[2-[[2-(4-morpholinyl)-1-oxoethyl]amino]ethyl]-3-oxanyl]benzamide
2-fluoro-N-[(2R,3R,6S)-2-(hydroxymethyl)-6-[2-[[2-(4-morpholinyl)-1-oxoethyl]amino]ethyl]-3-oxanyl]benzamide
3-[(3aS,4S,9bS)-4-(hydroxymethyl)-1-(2-methoxy-1-oxoethyl)-2,3,3a,4,5,9b-hexahydropyrrolo[3,2-c]quinolin-8-yl]-N,N-dimethylbenzamide
C24H29N3O4 (423.21579540000005)
3-[(3aS,4R,9bS)-4-(hydroxymethyl)-1-(2-methoxy-1-oxoethyl)-2,3,3a,4,5,9b-hexahydropyrrolo[3,2-c]quinolin-8-yl]-N,N-dimethylbenzamide
C24H29N3O4 (423.21579540000005)
(8R,9R,10S)-N-(4-fluorophenyl)-10-(hydroxymethyl)-9-[4-[(E)-prop-1-enyl]phenyl]-1,6-diazabicyclo[6.2.0]decane-6-carboxamide
(8S,9R,10R)-N-(4-fluorophenyl)-10-(hydroxymethyl)-9-[4-[(E)-prop-1-enyl]phenyl]-1,6-diazabicyclo[6.2.0]decane-6-carboxamide
(8S,9S,10R)-N-(4-fluorophenyl)-10-(hydroxymethyl)-9-[4-[(E)-prop-1-enyl]phenyl]-1,6-diazabicyclo[6.2.0]decane-6-carboxamide
(8R,9S,10R)-N-(4-fluorophenyl)-10-(hydroxymethyl)-9-[4-[(E)-prop-1-enyl]phenyl]-1,6-diazabicyclo[6.2.0]decane-6-carboxamide
(8S,9S,10S)-N-(4-fluorophenyl)-10-(hydroxymethyl)-9-[4-[(E)-prop-1-enyl]phenyl]-1,6-diazabicyclo[6.2.0]decane-6-carboxamide
[(1S)-2-[(4-fluorophenyl)methyl]-7-methoxy-1-methyl-1-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,4-piperidine]yl]methanol
(6R,7R,8R)-N-cyclopentyl-8-(hydroxymethyl)-7-[4-(4-methylpent-1-ynyl)phenyl]-2-oxo-1,4-diazabicyclo[4.2.0]octane-4-carboxamide
(6S,7R,8S)-7-[4-(3-cyclopentylprop-1-ynyl)phenyl]-8-(hydroxymethyl)-2-oxo-N-propyl-1,4-diazabicyclo[4.2.0]octane-4-carboxamide
(6R,7S,8S)-7-[4-(3-cyclopentylprop-1-ynyl)phenyl]-8-(hydroxymethyl)-2-oxo-N-propyl-1,4-diazabicyclo[4.2.0]octane-4-carboxamide
(6R,7S,8R)-7-[4-(3-cyclopentylprop-1-ynyl)phenyl]-8-(hydroxymethyl)-2-oxo-N-propyl-1,4-diazabicyclo[4.2.0]octane-4-carboxamide
(6S,7R,8R)-7-[4-(3-cyclopentylprop-1-ynyl)phenyl]-8-(hydroxymethyl)-2-oxo-N-propyl-1,4-diazabicyclo[4.2.0]octane-4-carboxamide
(6R,7R,8R)-7-[4-(3-cyclopentylprop-1-ynyl)phenyl]-8-(hydroxymethyl)-2-oxo-N-propyl-1,4-diazabicyclo[4.2.0]octane-4-carboxamide
(2S,3R)-1-(2-cyclopropyl-1-oxoethyl)-N-(2-fluorophenyl)-2-(hydroxymethyl)-3-phenyl-1,6-diazaspiro[3.3]heptane-6-carboxamide
(2S,3S)-1-(2-cyclopropyl-1-oxoethyl)-N-(2-fluorophenyl)-2-(hydroxymethyl)-3-phenyl-1,6-diazaspiro[3.3]heptane-6-carboxamide
(2R,3R)-1-(2-cyclopropyl-1-oxoethyl)-N-(2-fluorophenyl)-2-(hydroxymethyl)-3-phenyl-1,6-diazaspiro[3.3]heptane-6-carboxamide
2-cyclopropyl-1-[(1S)-2-(cyclopropylmethyl)-1-(hydroxymethyl)-7-methoxy-9-methyl-1-spiro[1,3-dihydropyrido[3,4-b]indole-4,3-azetidine]yl]ethanone
[(1S)-1-[(2-fluorophenyl)methyl]-7-methoxy-9-methyl-1-spiro[2,3-dihydro-1H-pyrido[3,4-b]indole-4,4-piperidine]yl]methanol
[(1R)-1-[(2-fluorophenyl)methyl]-7-methoxy-9-methyl-1-spiro[2,3-dihydro-1H-pyrido[3,4-b]indole-4,4-piperidine]yl]methanol
(6R,7R,8S)-7-[4-(1-cyclohexenyl)phenyl]-N-cyclopentyl-8-(hydroxymethyl)-2-oxo-1,4-diazabicyclo[4.2.0]octane-4-carboxamide
(1S,9R,10R,11R)-N-(1,3-benzodioxol-5-ylmethyl)-10-(hydroxymethyl)-6-oxo-5-[(E)-prop-1-enyl]-7,12-diazatricyclo[7.2.1.02,7]dodeca-2,4-diene-11-carboxamide
(1R,9S,10S,11S)-N-(1,3-benzodioxol-5-ylmethyl)-10-(hydroxymethyl)-6-oxo-5-[(E)-prop-1-enyl]-7,12-diazatricyclo[7.2.1.02,7]dodeca-2,4-diene-11-carboxamide
2-aminoethyl [2-hydroxy-3-[(Z)-pentadec-9-enoxy]propyl] hydrogen phosphate
C20H42NO6P (423.27496020000007)
[3-[2-aminoethoxy(hydroxy)phosphoryl]oxy-2-hydroxypropyl] (Z)-tetradec-9-enoate
C19H38NO7P (423.23857680000003)
(2S,3R)-2-(Acetylamino)octadecane-1,3-diol 1-phosphoric acid
C20H42NO6P (423.27496020000007)
cis-5-(6-(1,3-Dioxan-2-YL)hexyl)-trans-4-formyl-2,ref.-3-diphenylisoxazolidine
(E)-10,16-dichloro-N-(1-hydroxy-3-methoxypropan-2-yl)-N-methylhexadec-4-enamide
2-[[(E)-2-acetamido-3-hydroxydodec-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
C19H40N2O6P+ (423.26238500000005)
2-[[(E)-2-(butanoylamino)-3-hydroxydec-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
C19H40N2O6P+ (423.26238500000005)
2-[hydroxy-[(E)-3-hydroxy-2-(propanoylamino)undec-4-enoxy]phosphoryl]oxyethyl-trimethylazanium
C19H40N2O6P+ (423.26238500000005)
2-[hydroxy-[(E)-3-hydroxy-2-(pentanoylamino)non-4-enoxy]phosphoryl]oxyethyl-trimethylazanium
C19H40N2O6P+ (423.26238500000005)
2-[[(E)-2-(hexanoylamino)-3-hydroxyoct-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
C19H40N2O6P+ (423.26238500000005)
1-(9Z-tetradecenoyl)-glycero-3-phosphoethanolamine
C19H38NO7P (423.23857680000003)
pravastatin(1-)
A monocarboxylic acid anion resulting from the deprotonation of the carboxylic acid group of pravastatin.
4-Chloro-alpha-[4-[2-(diethylamino)ethoxy]phenyl]-alpha-phenylbenzeneethanol
Florosenine
A pyrrolizine alkaloid that is otosenine in which the hydroxy hydrogen has been replaced by an acetyl group.
4,6-dideoxy-4-(2-methoxypropanamido)-3-C-Me-L-Manp2Me-(1->3)-Fucp
An amido disaccharide comprising 4,6-dideoxy-4-(2-methoxypropanamido)-3-C-methyl-2-O-methyl-L-mannopyranose linked through the anomeric carbon to the 3-hydroxy group of L-fucose.
beta-anthropyranosyl-(1->3)-alpha-L-rhamnopyranose
An amino disaccharide consisting of alpha-L-rhamnopyranose having a beta-anthropyranosyl residue attached at the 3-position.
LPC(12:1)
C20H42NO6P (423.27496020000007)
Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved
FAUC 346
C24H29N3O2S (423.19803740000003)
FAUC 346, a highly selective D3 partial agonist (EC50 = 1.5 nM)[1][2].
(4e,7s)-n-[(2e)-3-chloro-2-[(5s)-2,5-dimethyl-6-oxocyclohex-1-en-1-yl]prop-2-en-1-yl]-7-methoxydodec-4-enimidic acid
C24H38ClNO3 (423.25400680000007)
(9s,15r,17s)-6-hydroxy-5-methoxy-2,18-dioxa-10-azapentacyclo[20.2.2.1⁹,¹⁷.0³,⁸.0¹⁰,¹⁵]heptacosa-1(24),3(8),4,6,22,25-hexaen-19-one
C25H29NO5 (423.20456240000004)
(20r)-4,5,6,10,11-pentamethoxy-16-azapentacyclo[12.7.0.0²,⁷.0⁸,¹³.0¹⁶,²⁰]henicosa-1(14),2(7),3,5,8(13),9,11-heptaene
C25H29NO5 (423.20456240000004)
6-hydroxy-9-(2-methylbut-3-en-2-yl)-4-(2-methylpropyl)-16-propanoyl-2,5,16-triazatetracyclo[7.7.0.0²,⁷.0¹⁰,¹⁵]hexadeca-5,10,12,14-tetraen-3-one
(1r,3'r,4r,6r,7s)-3',6,7,14-tetramethyl-3,8,17-trioxo-2,9-dioxa-14-azaspiro[bicyclo[9.5.1]heptadecane-4,2'-oxiran]-11-en-7-yl acetate
(1s,2s,3s,4s,5r,6r,8s,9r,10s,13s,16r,17r)-11-ethyl-6-methoxy-13-(methoxymethyl)-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecane-4,8,9,16-tetrol
C23H37NO6 (423.26207420000003)
[(1r,4z,6s,7r,11z)-4-ethylidene-7-hydroxy-7,14-dimethyl-3,8,17-trioxo-2,9-dioxa-14-azabicyclo[9.5.1]heptadec-11-en-6-yl]methyl acetate
(1s,2r,3r,4r,5s,6s,8r,9r,10r,13s,16r,17r,18s)-11-ethyl-6-methoxy-13-(methoxymethyl)-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecane-4,8,16,18-tetrol
C23H37NO6 (423.26207420000003)
(1s,17s,19r)-4,9-dihydroxy-5-methoxy-16-oxa-24-azapentacyclo[15.7.1.1⁸,¹².0²,⁷.0¹⁹,²⁴]hexacosa-2(7),3,5,8(26),9,11-hexaen-15-one
C25H29NO5 (423.20456240000004)
(1s,4s,6s,8s,9r,10r,13s,16s,17r,18s)-11-ethyl-13-(hydroxymethyl)-6,18-dimethoxy-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecane-4,8,16-triol
C23H37NO6 (423.26207420000003)
(1s,2s,4s,6s,9s,10s,11r,13s,15s,16r,17r,18r,19s)-8-ethyl-13,19-dimethoxy-5-oxa-8-azaheptacyclo[8.7.2.1¹⁴,¹⁷.0¹,⁹.0⁴,⁶.0⁶,¹⁸.0¹¹,¹⁶]icosane-2,10,11,15-tetrol
C22H33NO7 (423.22569080000005)
6,9-dihydroxy-5-methoxy-16-oxa-24-azapentacyclo[15.7.1.1⁸,¹².0²,⁷.0¹⁹,²⁴]hexacosa-2,4,6,8(26),9,11-hexaen-15-one
C25H29NO5 (423.20456240000004)
5-hydroxy-3-[(7-{[3-(hydroxymethyl)-3-methyloxiran-2-yl]methyl}-2-(2-methylbut-3-en-2-yl)-1h-indol-3-yl)methylidene]-6-methyl-1,6-dihydropyrazin-2-one
C24H29N3O4 (423.21579540000005)
11-ethyl-13-(hydroxymethyl)-6,16-dimethoxy-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecane-4,8,9-triol
C23H37NO6 (423.26207420000003)
(2s,4r,9as)-4-(3-hydroxy-4-methoxyphenyl)-octahydro-1h-quinolizin-2-yl (2e)-3-(4-hydroxyphenyl)prop-2-enoate
C25H29NO5 (423.20456240000004)
(1r,3'r,4r,6s,7r,11z)-3',6,7,14-tetramethyl-3,8,17-trioxo-2,9-dioxa-14-azaspiro[bicyclo[9.5.1]heptadecane-4,2'-oxiran]-11-en-7-yl acetate
(1r,3's,4s,6r,7r,11z)-3',6,7,14-tetramethyl-3,8,17-trioxo-2,9-dioxa-14-azaspiro[bicyclo[9.5.1]heptadecane-4,2'-oxiran]-11-en-7-yl acetate
1-[(2r,6s)-6-[4-(4-hydroxyphenyl)-2-oxobutyl]piperidin-2-yl]-4-(4-methoxyphenyl)butan-2-one
(1s,17s,19s)-4,9-dihydroxy-5-methoxy-16-oxa-24-azapentacyclo[15.7.1.1⁸,¹².0²,⁷.0¹⁹,²⁴]hexacosa-2(7),3,5,8(26),9,11-hexaen-15-one
C25H29NO5 (423.20456240000004)
11-ethyl-6-methoxy-13-(methoxymethyl)-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecane-4,8,9,16-tetrol
C23H37NO6 (423.26207420000003)
11-ethyl-6-methoxy-13-(methoxymethyl)-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecane-4,8,16,18-tetrol
C23H37NO6 (423.26207420000003)
(1r,3'r,4s,6r,7s,11z)-3',6,7,14-tetramethyl-3,8,17-trioxo-2,9-dioxa-14-azaspiro[bicyclo[9.5.1]heptadecane-4,2'-oxiran]-11-en-7-yl acetate
10-hydroxy-6-methoxy-8,17-dioxa-25-azapentacyclo[16.7.1.1⁹,¹³.0²,⁷.0²⁰,²⁵]heptacosa-2(7),3,5,9(27),10,12-hexaen-16-one
C25H29NO5 (423.20456240000004)
(3r)-3-[(3s)-3-(2-hydroxypropan-2-yl)-7-methyl-2,3-dihydro-1,4-benzodioxin-5-yl]-4-(3-methylbut-2-en-1-yl)-3h-isoindole-1,7-diol
C25H29NO5 (423.20456240000004)
(1r,3'r,4r,6r,7r,11z)-3',6,7,14-tetramethyl-3,8,17-trioxo-2,9-dioxa-14-azaspiro[bicyclo[9.5.1]heptadecane-4,2'-oxiran]-11-en-7-yl acetate
4,9-dihydroxy-5-methoxy-16-oxa-24-azapentacyclo[15.7.1.1⁸,¹².0²,⁷.0¹⁹,²⁴]hexacosa-2(7),3,5,8(26),9,11-hexaen-15-one
C25H29NO5 (423.20456240000004)
(2s,3s,4s)-4-amino-2,3-dihydroxy-n-[(1s)-1-[(3s)-8-hydroxy-1-oxo-3,4-dihydro-2-benzopyran-3-yl]-3-methylbutyl]hexanediimidic acid
11-ethyl-4,6,16-trimethoxy-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecane-8,9,18-triol
C23H37NO6 (423.26207420000003)
(1r,2r,3r,4s,5r,6s,8s,9r,10s,13r,16r,17r)-11-ethyl-16-methoxy-13-(methoxymethyl)-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecane-4,6,8,17-tetrol
C23H37NO6 (423.26207420000003)
(2s,4z)-5-hydroxy-4-[(2e,4e,6e,8r,10r)-1-hydroxy-6,8,10-trimethyldodeca-2,4,6-trien-1-ylidene]-2-[(4-hydroxyphenyl)methyl]-2h-pyrrol-3-one
(1s,2r,3r,4s,5s,6s,8r,9r,10s,13s,16s,17r)-11-ethyl-13-(hydroxymethyl)-6,16-dimethoxy-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecane-4,8,9-triol
C23H37NO6 (423.26207420000003)
5-hydroxy-2-[(4-hydroxyphenyl)methyl]-4-[(2e,4e,6e,8r,10r)-6,8,10-trimethyldodeca-2,4,6-trienoyl]-1,2-dihydropyrrol-3-one
(1r,2s,3r,4s,5s,6s,8s,9s,10r,13s,16s,17r)-11-ethyl-6-methoxy-13-(methoxymethyl)-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecane-2,4,8,16-tetrol
C23H37NO6 (423.26207420000003)
1,3,5-trihydroxy-4-methoxy-10-methyl-2,8-bis(3-methylbut-2-en-1-yl)acridin-9-one
C25H29NO5 (423.20456240000004)
11-ethyl-6,18-dimethoxy-13-methyl-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecane-4,8,9,16-tetrol
C23H37NO6 (423.26207420000003)
(1s,2r,3r,4s,5s,6r,7s,8s,9s,10r,13s,16s,17r)-11-ethyl-6-methoxy-13-(methoxymethyl)-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecane-4,7,8,16-tetrol
C23H37NO6 (423.26207420000003)
4,5,6,10,11-pentamethoxy-16-azapentacyclo[12.7.0.0²,⁷.0⁸,¹³.0¹⁶,²⁰]henicosa-1(14),2(7),3,5,8(13),9,11-heptaene
C25H29NO5 (423.20456240000004)
3',6,7,14-tetramethyl-3,8,17-trioxo-2,9-dioxa-14-azaspiro[bicyclo[9.5.1]heptadecane-4,2'-oxiran]-11-en-7-yl acetate
n-[3-chloro-2-(6-oxocyclohex-1-en-1-yl)prop-2-en-1-yl]-7-methoxytetradec-4-enimidic acid
C24H38ClNO3 (423.25400680000007)
(1r,4s,5s,6s,8r,9s,10s,13s,16s,18s)-11-ethyl-4,6,18-trimethoxy-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecane-8,13,16-triol
C23H37NO6 (423.26207420000003)
(2s,3r,4r)-4-amino-2,3-dihydroxy-n-[(1r)-1-[(3s)-8-hydroxy-1-oxo-3,4-dihydro-2-benzopyran-3-yl]-3-methylbutyl]hexanediimidic acid
(4e,7s)-n-[(2z)-3-chloro-2-(6-oxocyclohex-1-en-1-yl)prop-2-en-1-yl]-7-methoxytetradec-4-enimidic acid
C24H38ClNO3 (423.25400680000007)
4-hydroxy-5-methoxy-2,18-dioxa-10-azapentacyclo[20.2.2.1⁹,¹⁷.0³,⁸.0¹⁰,¹⁵]heptacosa-1(24),3,5,7,22,25-hexaen-19-one
C25H29NO5 (423.20456240000004)
14-hydroxy-16-[2-hydroxy-2-(2-hydroxy-4,5-dihydro-1,3-thiazol-4-yl)ethyl]-4,11-dimethyl-1-oxacyclohexadeca-3,7,9-trien-2-one
C22H33NO5S (423.2079328000001)
(1r,3'r,6r,7s,11z)-3',6,7,14-tetramethyl-3,8,17-trioxo-2,9-dioxa-14-azaspiro[bicyclo[9.5.1]heptadecane-4,2'-oxiran]-11-en-7-yl acetate
(4z)-5-hydroxy-4-[(2e,4e,6e,8r,10r)-1-hydroxy-6,8,10-trimethyldodeca-2,4,6-trien-1-ylidene]-2-[(4-hydroxyphenyl)methyl]-2h-pyrrol-3-one
(1s,2r,3r,4s,5s,6s,8r,9r,10r,13s,16s,17r,18r)-11-ethyl-13-(hydroxymethyl)-6,18-dimethoxy-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecane-4,8,16-triol
C23H37NO6 (423.26207420000003)
(1s,2r,3r,4s,5s,6s,8r,9s,10s,13r,16s,17r,18r)-11-ethyl-6,8-dimethoxy-13-methyl-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecane-4,9,16,18-tetrol
C23H37NO6 (423.26207420000003)
9-acetyl-3-(3,5-dimethylhepta-1,3-dien-1-yl)-2-(2-hydroxyethyl)-6a-methylfuro[2,3-h]isoquinoline-6,8-dione
C25H29NO5 (423.20456240000004)
(1r,2r,3r,4r,5s,6s,8r,9r,10r,13s,16r,17s,18s)-11-ethyl-6,18-dimethoxy-13-methyl-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecane-4,8,9,16-tetrol
C23H37NO6 (423.26207420000003)
{4-ethylidene-7-hydroxy-7,14-dimethyl-3,8,17-trioxo-2,9-dioxa-14-azabicyclo[9.5.1]heptadec-11-en-6-yl}methyl acetate
(4e)-10,16-dichloro-n-[(2r)-1-hydroxy-3-methoxypropan-2-yl]-n-methylhexadec-4-enamide
(2r,3r,4s,5s,6s,8r,13s,17r)-11-ethyl-13-(hydroxymethyl)-6,18-dimethoxy-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecane-4,8,16-triol
C23H37NO6 (423.26207420000003)
(1r,7ar)-7-({[(2s)-2-[(1s)-1-(acetyloxy)ethyl]-2-hydroxy-3-methylbutanoyl]oxy}methyl)-2,3,5,7a-tetrahydro-1h-pyrrolizin-1-yl (2e)-2-methylbut-2-enoate
C22H33NO7 (423.22569080000005)
4-(3-hydroxy-4-methoxyphenyl)-octahydro-1h-quinolizin-2-yl 3-(4-hydroxyphenyl)prop-2-enoate
C25H29NO5 (423.20456240000004)
n-{4-[(3s)-3-benzoyl-3-hydroxy-4-methyl-2-oxo-1,4-diazepan-1-yl]butyl}benzenecarboximidic acid
C24H29N3O4 (423.21579540000005)
5-hydroxy-4-(1-hydroxy-6,8,10-trimethyldodeca-2,4,6-trien-1-ylidene)-2-[(4-hydroxyphenyl)methyl]-2h-pyrrol-3-one
11-ethyl-13-(hydroxymethyl)-6,18-dimethoxy-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecane-4,8,16-triol
C23H37NO6 (423.26207420000003)
(9s,15s,17s)-6-hydroxy-5-methoxy-2,18-dioxa-10-azapentacyclo[20.2.2.1⁹,¹⁷.0³,⁸.0¹⁰,¹⁵]heptacosa-1(24),3(8),4,6,22,25-hexaen-19-one
C25H29NO5 (423.20456240000004)
(1s,2s,4s,6s,9s,10s,11r,13s,14s,15s,16r,17r,18r,19s)-8-ethyl-13,19-dimethoxy-5-oxa-8-azaheptacyclo[8.7.2.1¹⁴,¹⁷.0¹,⁹.0⁴,⁶.0⁶,¹⁸.0¹¹,¹⁶]icosane-2,10,11,15-tetrol
C22H33NO7 (423.22569080000005)
(1r,3'r,4r,6r,7s,11z)-3',6,7,14-tetramethyl-3,8,17-trioxo-2,9-dioxa-14-azaspiro[bicyclo[9.5.1]heptadecane-4,2'-oxiran]-11-en-7-yl acetate
(1s,2r,3r,4s,5s,6s,8s,9r,10r,13s,16s,17r,18s)-11-ethyl-13-(hydroxymethyl)-6,18-dimethoxy-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecane-4,8,16-triol
C23H37NO6 (423.26207420000003)
(4e,7s)-n-[(2e)-3-chloro-2-(6-oxocyclohex-1-en-1-yl)prop-2-en-1-yl]-7-methoxytetradec-4-enimidic acid
C24H38ClNO3 (423.25400680000007)
(1s,2r,3r,4s,5s,6s,8r,9r,10s,13s,16s,17r)-11-ethyl-6-methoxy-13-(methoxymethyl)-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecane-4,8,9,16-tetrol
C23H37NO6 (423.26207420000003)
(9s,15s,17r)-4-hydroxy-5-methoxy-2,18-dioxa-10-azapentacyclo[20.2.2.1⁹,¹⁷.0³,⁸.0¹⁰,¹⁵]heptacosa-1(24),3,5,7,22,25-hexaen-19-one
C25H29NO5 (423.20456240000004)
n-[3-chloro-2-(2,5-dimethyl-6-oxocyclohex-1-en-1-yl)prop-2-en-1-yl]-7-methoxydodec-4-enimidic acid
C24H38ClNO3 (423.25400680000007)
(2s,3s)-4-{[(7r,7ar)-7-(acetyloxy)-5,6,7,7a-tetrahydro-3h-pyrrolizin-1-yl]methoxy}-3-hydroxy-3-isopropyl-4-oxobutan-2-yl (2e)-2-methylbut-2-enoate
C22H33NO7 (423.22569080000005)
(6as)-9-acetyl-3-[(1e,5s)-3,5-dimethylhepta-1,3-dien-1-yl]-2-(2-hydroxyethyl)-6a-methylfuro[2,3-h]isoquinoline-6,8-dione
C25H29NO5 (423.20456240000004)
11-ethyl-6-methoxy-13-(methoxymethyl)-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecane-2,4,8,16-tetrol
C23H37NO6 (423.26207420000003)
4-amino-2,3-dihydroxy-n-[1-(8-hydroxy-1-oxo-3,4-dihydro-2-benzopyran-3-yl)-3-methylbutyl]hexanediimidic acid
3-[3-(2-hydroxypropan-2-yl)-7-methyl-2,3-dihydro-1,4-benzodioxin-5-yl]-4-(3-methylbut-2-en-1-yl)-3h-isoindole-1,7-diol
C25H29NO5 (423.20456240000004)
(1s,17s,19r)-6,9-dihydroxy-5-methoxy-16-oxa-24-azapentacyclo[15.7.1.1⁸,¹².0²,⁷.0¹⁹,²⁴]hexacosa-2,4,6,8(26),9,11-hexaen-15-one
C25H29NO5 (423.20456240000004)
(1s,2r,3r,4s,5s,6s,8r,9r,10r,13s,16s,17r,18r)-11-ethyl-6-methoxy-13-(methoxymethyl)-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecane-4,8,16,18-tetrol
C23H37NO6 (423.26207420000003)
11-ethyl-4,6,16-trimethoxy-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecane-8,13,18-triol
C23H37NO6 (423.26207420000003)
3-[(2s,5s,8s)-5,8-dibenzyl-3,6,9-trihydroxy-5,8-dihydro-2h-1,4,7-triazonin-2-yl]propanoic acid
(1r,4s,7s,9r)-6-hydroxy-9-(2-methylbut-3-en-2-yl)-4-(2-methylpropyl)-16-propanoyl-2,5,16-triazatetracyclo[7.7.0.0²,⁷.0¹⁰,¹⁵]hexadeca-5,10,12,14-tetraen-3-one
(4e,7s)-n-[(2e)-3-chloro-2-(2,5-dimethyl-6-oxocyclohex-1-en-1-yl)prop-2-en-1-yl]-7-methoxydodec-4-enimidic acid
C24H38ClNO3 (423.25400680000007)
(3s)-3-[(3s)-3-(2-hydroxypropan-2-yl)-7-methyl-2,3-dihydro-1,4-benzodioxin-5-yl]-4-(3-methylbut-2-en-1-yl)-3h-isoindole-1,7-diol
C25H29NO5 (423.20456240000004)
(1r,3's,6r,7r)-3',6,7,14-tetramethyl-3,8,17-trioxo-2,9-dioxa-14-azaspiro[bicyclo[9.5.1]heptadecane-4,2'-oxiran]-11-en-7-yl acetate
5-amino-2,3-dihydroxy-n-[1-(8-hydroxy-1-oxo-3,4-dihydro-2-benzopyran-3-yl)-3-methylbutyl]hexanediimidic acid
11-ethyl-6-methoxy-13-(methoxymethyl)-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecane-4,7,8,16-tetrol
C23H37NO6 (423.26207420000003)
(1s,2r,3r,4s,5r,6s,8r,9s,10s,13r,16s,17r,18s)-11-ethyl-4,6,16-trimethoxy-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecane-8,9,18-triol
C23H37NO6 (423.26207420000003)
n-[4-(3-benzoyl-3-hydroxy-4-methyl-2-oxo-1,4-diazepan-1-yl)butyl]benzenecarboximidic acid
C24H29N3O4 (423.21579540000005)
2-[(1r,4e,6s,7r,11z)-7-hydroxy-6,7,14-trimethyl-3,8,17-trioxo-2,9-dioxa-14-azabicyclo[9.5.1]heptadec-11-en-4-ylidene]ethyl acetate
(3z,6s)-3-[(7-{[(2r,3r)-3-(hydroxymethyl)-3-methyloxiran-2-yl]methyl}-2-(2-methylbut-3-en-2-yl)-1h-indol-3-yl)methylidene]-6-methyl-6h-pyrazine-2,5-diol
C24H29N3O4 (423.21579540000005)
(1s,2r,3r,4s,5s,6s,8r,9r,10s,13r,16s,17r,18s)-11-ethyl-6,18-dimethoxy-13-methyl-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecane-4,8,9,16-tetrol
C23H37NO6 (423.26207420000003)
(9s,15r,17s)-4-hydroxy-5-methoxy-2,18-dioxa-10-azapentacyclo[20.2.2.1⁹,¹⁷.0³,⁸.0¹⁰,¹⁵]heptacosa-1(24),3,5,7,22,25-hexaen-19-one
C25H29NO5 (423.20456240000004)
(1s,18s,20r)-10-hydroxy-6-methoxy-8,17-dioxa-25-azapentacyclo[16.7.1.1⁹,¹³.0²,⁷.0²⁰,²⁵]heptacosa-2(7),3,5,9(27),10,12-hexaen-16-one
C25H29NO5 (423.20456240000004)
13-methyl-7-(3-methylbut-2-en-1-yl)-12-[(3-methylbut-2-en-1-yl)oxy]-9-azatricyclo[9.4.0.0³,⁸]pentadeca-1(11),3,5,7,9,12,14-heptaene-2,4,10,15-tetrol
C25H29NO5 (423.20456240000004)
(1r,2s,3s,4s,5r,6s,8s,9s,10r,13s,16s,17s)-11-ethyl-4,6,16-trimethoxy-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecane-3,8,13-triol
C23H37NO6 (423.26207420000003)
(1s,17s,19s)-6,9-dihydroxy-5-methoxy-16-oxa-24-azapentacyclo[15.7.1.1⁸,¹².0²,⁷.0¹⁹,²⁴]hexacosa-2,4,6,8(26),9,11-hexaen-15-one
C25H29NO5 (423.20456240000004)
(1s,2r,3r,4s,5s,6s,8r,9r,10r,13s,16s,17r,18s)-11-ethyl-6-methoxy-13-(methoxymethyl)-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecane-4,8,16,18-tetrol
C23H37NO6 (423.26207420000003)
5-hydroxy-4-[(2e,4e,6r,7r,8s,9s,11r,12r)-1,7,9,11-tetrahydroxy-4,6,8,12-tetramethyl-13-oxotetradeca-2,4-dien-1-ylidene]-2h-pyrrol-3-one
C22H33NO7 (423.22569080000005)
(7s)-n-[3-chloro-2-(6-oxocyclohex-1-en-1-yl)prop-2-en-1-yl]-7-methoxytetradec-4-enimidic acid
C24H38ClNO3 (423.25400680000007)
(1r,3's,6r,7r,11z)-3',6,7,14-tetramethyl-3,8,17-trioxo-2,9-dioxa-14-azaspiro[bicyclo[9.5.1]heptadecane-4,2'-oxiran]-11-en-7-yl acetate
6-hydroxy-5-methoxy-2,18-dioxa-10-azapentacyclo[20.2.2.1⁹,¹⁷.0³,⁸.0¹⁰,¹⁵]heptacosa-1(24),3(8),4,6,22,25-hexaen-19-one
C25H29NO5 (423.20456240000004)
(2r)-13-methyl-7-(3-methylbut-2-en-1-yl)-12-[(3-methylbut-2-en-1-yl)oxy]-9-azatricyclo[9.4.0.0³,⁸]pentadeca-1(11),3,5,7,9,12,14-heptaene-2,4,10,15-tetrol
C25H29NO5 (423.20456240000004)
(1s,2r,3r,4s,5s,6s,8r,9s,10s,13r,16s,17r,18s)-11-ethyl-6,18-dimethoxy-13-methyl-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecane-4,8,9,16-tetrol
C23H37NO6 (423.26207420000003)
(3z,7e,9z,11s,14r,16r)-14-hydroxy-16-[(2r)-2-hydroxy-2-[(4r)-2-hydroxy-4,5-dihydro-1,3-thiazol-4-yl]ethyl]-4,11-dimethyl-1-oxacyclohexadeca-3,7,9-trien-2-one
C22H33NO5S (423.2079328000001)